NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.84% | -21.92% | -20.27% | 11.46% | -40.02% |
| Total Depreciation and Amortization | 55.56% | 49.02% | 20.50% | 18.12% | 19.74% |
| Total Amortization of Deferred Charges | 0.19% | -- | -- | -- | 12.06% |
| Total Other Non-Cash Items | -72.69% | 6.28% | 7.77% | -26.64% | 1,076.74% |
| Change in Net Operating Assets | -431.62% | 94.04% | -296.54% | -2.80% | -79.20% |
| Cash from Operations | -421.70% | 98.28% | -826.51% | -12.96% | 76.29% |
| Capital Expenditure | 45.25% | 47.07% | 52.07% | 9.95% | -31.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,671.57% | 269.28% | 111.42% | -98.40% | -112.60% |
| Cash from Investing | 1,614.23% | 600.83% | 109.61% | -102.63% | -122.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -40.52% | 438.00% | -27.84% | 2,363.38% | 40.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20,937.77% | 100,417.00% | -97.27% | 2,363.38% | 40.58% |
| Foreign Exchange rate Adjustments | 40.63% | -125.29% | 444.16% | 505.36% | -164.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -944.14% | 827.47% | 107.86% | -117.07% | -126.85% |